Planes, Trains, Automobiles, and Pharmaceuticals

CENTRE DE RECHERCHE DE ST. MARY PRÉSENTE :
ST. MARY’S RESEARCH CENTRE PRESENTS:
Planes, Trains, Automobiles, and Pharmaceuticals:
Safety Lessons Learned from the Southern Network
on Adverse Reactions
~~~
Charles L Bennett, MD, PhD, MPP
Director, Center for Medication Safety
Endowed Chair in Medication Safety and Efficacy, South Carolina Center for Economic Excellence in Medication
Safety and Efficacy
Frank P and Josie M Fletcher Professor of Pharmacy, South Carolina College of Pharmacy
Adjunct Professor, Arnold School of Public Health, University of South Carolina
Staff Physician, Dorn Veterans Administration Hospital
********************************************************
DATE ET HEURE / DATE AND TIME
Le lundi 5 novembre 2012 / Monday Novembre 5, 2012
12:00 -13:00
ENDROIT / LOCATION
Auditorium
Centre hospitalier de St. Mary / St. Mary’s Hospital Center
Un léger dîner sera servi / A light lunch will be served
Bienvenue à tous / Everyone is welcome
ABSTRACT
Charles L Bennett MD PhD MPP, South Carolina Center of Economic Excellence Chair for
Medication Safety and Efficacy at the South Carolina College of Pharmacy and the Hollings
Cancer Center of the Medical University of South Carolina will present an overview of the recent
findings from the Southern Network on Adverse Reactions (SONAR).
The SONAR program is the only state-funded pharmacovigilance initiative in North America that
seeks to identify potentially fatal toxicities of drugs that have not been identified by the
regulatory agencies and the pharmaceutical manufacturers. In this presentation, we will review
the scientific investigations that led to some of the more recent SONAR findings- including
rituximab-associated progressive multifocal leukoencephalopathy, gadodiamide associated
nephrogenic systemic fibrosis, erythropoietin and darbepoetin-associated mortality and venous
thromboembolism, and ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic
purpura. We will also briefly review the first hand investigations that allowed myself, Denis
Cournoyer of McGill, Karen Starko of California, and Henrik Thomsen of Copenhagen to identify
three rare adverse drug reactions- pure red cell aplasia, nephrogenic systemic fibrosis, and
Reye’s syndrome. Finally, we will provide empirical findings that for the first time identify
conflicts of interest in pharmaceutical sponsored basic science research- a finding that may help
explain why serious adverse drug reactions are so difficult to identify in less than a 10 year
period.
Cette présentation sera en anglais seulement